Dianthus Therapeutics (NASDAQ:DNTH) Posts Quarterly Earnings Results, Misses Estimates By $0.46 EPS

Dianthus Therapeutics (NASDAQ:DNTH) announced its earnings results on Monday. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46), FiscalAI reports. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The business had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.40 million.

Here are the key takeaways from Dianthus Therapeutics’ conference call:

• Early “go” decision for the CAPTIVATE trial after the planned interim responder analysis — management says the Part A responder target was met earlier than expected for the 300 mg q2w regimen.
• The study design was revised — the 600 mg arm is being dropped and Part B will be a 2‑arm blinded RCT (300 mg q2w vs placebo), reducing Part B enrollment from 192 to 128 and lowering overall Part A dosing from 480 to 256 patients to accelerate timelines.
• Interim safety readout was described as reassuring with no concerning safety events reported, including no clinical signs of autoimmune activation, no worrisome bacterial infections, and no safety-related discontinuations.
• Management raised the Part A responder target from 40% to 50% but did not disclose specific responder rates or patient‑level data to protect trial integrity and cautioned the update is based on an interim analysis with a relatively small cohort.
• Multiple upcoming catalysts and solid funding — company expects CIDP top‑line later this year, plans a gMG Phase 3 start in mid‑2026, MMN and DNTH212 milestones in 2024, and reported approximately $514 million in cash to fund operations into 2028.

Dianthus Therapeutics Trading Up 21.5%

Shares of DNTH stock opened at $79.23 on Tuesday. Dianthus Therapeutics has a 12-month low of $13.36 and a 12-month high of $84.86. The stock has a market capitalization of $3.42 billion, a P/E ratio of -22.77 and a beta of 1.56. The firm’s 50 day moving average is $49.17 and its 200 day moving average is $41.17.

More Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision for the Phase 3 CAPTIVATE CIDP trial — the company reported it met the Part A responder criteria (20 confirmed responders with fewer than 40 completers) and will keep the 300mg S.C. dose while engaging regulators to remove the 600mg dose, accelerating the program toward the planned next steps. Early GO Decision Press Release
• Positive Sentiment: Multiple analyst upgrades and higher price targets have lifted sentiment and helped push DNTH to a new 12‑month high; this analyst momentum supports further upside expectations. Analyst Upgrade / 12-Month High
• Neutral Sentiment: Company hosted / scheduled a conference call and webcast to discuss the interim responder analysis (transcript and slides available) — useful for investors seeking detail on responder definitions and next steps but not new data beyond the GO decision. Conference Call / Webcast Notice
• Neutral Sentiment: Short interest data reported appears negligible/zero and does not presently signal a material short pressure or squeeze dynamic. (Entry data showed 0 shares short, 0.0 days to cover.)
• Negative Sentiment: Proposed $400 million underwritten public offering — the company announced a sizable equity raise (with a 30‑day option to upsize by $60M), which can be dilutive and likely caps near‑term upside until proceeds are deployed. Public Offering Announcement
• Negative Sentiment: Q4 earnings miss — DNTH reported a larger-than-expected GAAP loss (EPS -$1.43 vs. consensus -$0.97); while revenue beat nominally, the wider loss underscores current cash burn and execution risks. Q4 Results / Earnings Miss
• Negative Sentiment: New AI/cyber/privacy risk disclosure — the company flagged heightened cyber, privacy and reputational risks related to AI integration, a cautionary corporate‑governance/regulatory risk that could increase compliance costs or negative headlines. AI / Cyber Risk Disclosure

Analysts Set New Price Targets

A number of equities analysts recently weighed in on DNTH shares. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Monday. HC Wainwright boosted their price target on Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday. Jefferies Financial Group set a $98.00 price target on Dianthus Therapeutics and gave the stock a “buy” rating in a research note on Monday. Finally, Oppenheimer increased their price objective on Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research report on Monday. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $98.67.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Vestal Point Capital LP boosted its stake in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after buying an additional 1,499,931 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Dianthus Therapeutics by 3,366.9% in the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after acquiring an additional 2,503,311 shares during the period. TCG Crossover Management LLC lifted its holdings in Dianthus Therapeutics by 11.7% in the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after acquiring an additional 175,000 shares during the period. State Street Corp boosted its position in Dianthus Therapeutics by 124.7% in the fourth quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after purchasing an additional 836,571 shares during the last quarter. Finally, Braidwell LP lifted its stake in shares of Dianthus Therapeutics by 52.6% in the 4th quarter. Braidwell LP now owns 1,273,935 shares of the company’s stock worth $52,499,000 after purchasing an additional 438,878 shares during the period. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.